

CSU IBC Approved Minutes

Meeting title	CSU IBC Meeting January 2026
Date	January 21, 2026
Convened at	12:04 PM MST
Location	LSC Rm 322
Open or closed meeting (If closed, why?)	The meeting was closed briefly to discuss personal, proprietary, and/or security matters. The meeting was open the remainder of the time.
Review of prior meeting minutes	December 10, 2025, Meeting minutes approved as written.
Adjournment	12:48 PM MST
Recorded by	M. Ramey & C. Johnson

Attendees

Check if Attending (Members):	Check if Attending (Alternate Members):
<input checked="" type="checkbox"/> Jessica Ayers, Animal expert	<input type="checkbox"/> Lon Kendall, Director LAR
<input checked="" type="checkbox"/> Donald Bade, Unaffiliated	
<input checked="" type="checkbox"/> Angela Bosco-Lauth, Veterinary Virology	
<input checked="" type="checkbox"/> Chaoping Chen, Chair	
<input checked="" type="checkbox"/> Jason Cummings, lab representative	
<input checked="" type="checkbox"/> Dan Frazen, Unaffiliated	
<input checked="" type="checkbox"/> Brendan Podell, Mycobacteria specialist	
<input type="checkbox"/> Ann Powers, Virology	
<input checked="" type="checkbox"/> Robyn Roberts, Plant expert	
<input checked="" type="checkbox"/> Joanie Ryan, Assistant Biosafety Director	<input checked="" type="checkbox"/> Rebecca Moritz, Biosafety Office Director*
<input checked="" type="checkbox"/> Tony Schountz, Virology	<input checked="" type="checkbox"/> Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 6 voting members; 10 in attendance	*non-voting at this meeting
Non-Voting Members:	
<input type="checkbox"/>	
<input checked="" type="checkbox"/> Joni Van Sickle, Occupational Health Coord.	
ORCC Staff (non-voting):	
<input checked="" type="checkbox"/> Michelle Ramey, Assistant Compliance Coord.	<input checked="" type="checkbox"/> Sonia Aleman Rivera, Assistant Biosafety Officer
<input checked="" type="checkbox"/> Nicole Marlenee, Biosecurity Specialist	<input checked="" type="checkbox"/> Kelly Kim, Assistant Biosafety Officer
<input checked="" type="checkbox"/> Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
Mario Arango, OGC; 2 members of the public	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. Review of December 10, 2025, IBC meeting minutes

The minutes were approved as written.

2. Agent/Project Review

a. PI name/Lab	Lark Lab
Project Number and Title	26-004B: Tumor-mediated trafficking of extracellular vesicles
Project Overview	The goal of this study is to define how tumors contribute to cachexia in adipose tissue and skeletal muscle through release and delivery of extracellular vesicles (EVs).
Planned Modifications	They will inject transduced murine cancer cell lines into mice then track the extracellular vesicles released
Viral Vector Forms	<ul style="list-style-type: none"> Viral Vector Registration Form-CD63-eGFP Lentivirus
NIH Guidelines Section	III-D-4; III-E-1; III-E-3
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Discussion	<p>For the project:</p> <ol style="list-style-type: none"> Selection antibiotics is inconsistent: neomycin vs puromycin; please clarify. Animal Biosafety level indicates "ABSL2, unsure"; it is unclear what is meant by this. IBC requests a brief description of inactivation prior to disposal, including disinfectant used and its concentration be added. <p>For the Viral Vector form: The requests clarification regarding end destination of contaminated consumables</p>
Verification of training	All lab personnel training is current.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the agent and project with modifications described above (see Discussion)
Vote	The motion was unanimously approved.

3. Amendments requiring full IBC review

b. PI name/Lab	Thamm Lab
Project Number and Title	19-038B: Cellular Immunotherapy for Canine Cancers
Project Overview	Chimeric antigen receptors (CAR) will be transduced into primary canine T cells to generate CAR T cells that directly target antigens expressed on canine cancer cells. The T cells expressing the CAR will be used in a variety of in vitro assays and to treat purpose-bred laboratory dogs.

Planned Modifications	Generating CAR T cells
Agents used	<ul style="list-style-type: none"> • E. coli • 3rd generation SIN (self-inactivating) lentiviral vector
NIH Guidelines Section	III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Amendment request	Change the animal model from mice to dogs
Discussion	<ol style="list-style-type: none"> 1. The project indicates animals will be handled in a biosafety cabinet is marked YES. This should be changed to NO. 2. For in vivo PPE, the IBC recommends using either back closing gowns or scrubs in place of lab coats.
Motion	A motion was made to approve the amendment request with modifications described above (see Discussion).
Vote	The motion was unanimously approved.

4. New Business

None

5. Unfinished Business

a. NIH Initiative to Modernize and Strengthen Biosafety Oversight

(<https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy#tab2/>)

NIH is continuing with their listening sessions. Region 4 is scheduled for 1/29/26 and Region 5 (which includes CO) is scheduled for 2/12/26. Anyone can attend, but they do need to register. Committee members are encouraged to attend if they can.

6. Closed Session

7. Reports

a. Coordinator's Report	1. Next IBC meeting: Wednesday, February 11, 2026
b. Biosafety Office Report	<ol style="list-style-type: none"> 1. Inspections update: the Biosafety group has been conducting a lot of lab visits 2. 2025 Q4 Incident Reports: there were no incidents involving rDNA in Q4

8. Public Comment

No public comments were made at this meeting.

9. Items to be read into the minutes

a. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed	None
---	------